http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2252764-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 |
| filingDate | 2003-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_932a8d4abfc8e61a0f352e60b7ba927d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a4123978107a01746c37d0996dfe669 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06e03b148ccf7e3146f4f3f710a44fe4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c66d698acd75e7fe241f2e137345cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f735a831db54b7b2a9b0ea7ea7c5fd03 |
| publicationDate | 2005-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2252764-C2 |
| titleOfInvention | Method for complex treatment of lymphogranulematosis |
| abstract | FIELD: medicine. n SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1 st and the 8 th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1 st to the 14 th d - procarbazine and prednisolone; moreover, on the 1 st and the 8 th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles. n EFFECT: higher efficiency of therapy. n 2 ex |
| priorityDate | 2003-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.